SCHEMBL14224630

SCHEMBL14224630

Cn1cc(/C(C(N)=O)=C(/C=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCG P05129 5/20 0.56
PRKCB P05771 5/20 0.56
PRKCA P17252 5/20 0.56
PRKCE Q02156 5/20 0.56
PRKCH P24723 4/20 0.56
PRKCD Q05655 4/20 0.56
CAMK2D Q13557 4/20 0.56
PRKCZ Q05513 3/20 0.56
CAMK2B Q13554 3/20 0.56
CAMK2G Q13555 3/20 0.56
CAMK2A Q9UQM7 3/20 0.56
PIP5K1C O60331 1/20 0.56
RPS6KA5 O75582 1/20 0.56
RPS6KA4 O75676 1/20 0.56
STK16 O75716 1/20 0.56
PAK3 O75914 1/20 0.56
CDK14 O94921 1/20 0.56
MET P08581 1/20 0.56
PDGFRB P09619 1/20 0.56
KIT P10721 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13915330 0.76 PRKCG (0.55) PRKCGPRKCBPRKCAPRKCEPRKCH
SCHEMBL588318 0.76 PRKCG (0.55) PRKCGPRKCBPRKCAPRKCEPRKCH
SCHEMBL28297895 0.74 PRKCG (0.64) PRKCGPRKCBPRKCAPRKCEPRKCH
SCHEMBL30445335 0.74 PRKCG (0.51) PRKCGPRKCBPRKCAPRKCEPRKCH
Hydrochloric Acid SCHEMBL29784988 0.74 PRKCG (0.77) PRKCGPRKCBPRKCAPRKCEPRKCH
Hydrochloric Acid SCHEMBL27993565 0.73 PRKCG (0.65) PRKCGPRKCBPRKCAPRKCEPRKCH
SCHEMBL14555078 0.72 PRKCG (0.62) PRKCGPRKCBPRKCAPRKCEPRKCH
Enzastaurin SCHEMBL678748 0.72 PRKCG (1.00) PRKCGPRKCBPRKCAPRKCEPRKCH
Enzastaurin SCHEMBL29356867 0.72 PRKCG (1.00) PRKCGPRKCBPRKCAPRKCEPRKCH
Enzastaurin SCHEMBL29371538 0.72 PRKCG (1.00) PRKCGPRKCBPRKCAPRKCEPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096923-A1 Methods For Diagnosing And Treating Diabetic Microvascular Complications ELI LILLY AND COMPANY 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096923-A1 Methods For Diagnosing And Treating Diabetic Microvascular Complications FLT4, TEK, MAP3K13 PRKCG 559/4885PRKCB 286/4885PRKCA 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.